	M PTO-	-1380 U.S. DEPARTMENT C	OF COMMERCE PATENT AND TRADEWARK OUTSET	WAS A THE LIVE LA MUNICI LAVA	
			er to the united states	U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)	
			CTED OFFICE (DO/EO/US)	10/563,679	
10.176	TAIAT		LING UNDER 35 U.S.C. 371 I INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED	
INTERNATIONAL APPLICATION NO. PCT/FR2004/002050			30 July 2004	1 August 2003	
TITLE OF INVENTION					
novel anti-angiogenic agent and its use, in particular within the Framework of the treatment of Cancer					
APPLICANT(S) FOR DO/EO/US PLOUÊT of all.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1,		This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.			
2.	X	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.			
3.			This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.		
4.		The U.S. has been elected (Article 31).			
5.	A cc	opy of the International Application as filed (35 U.S.C. 371(c)(2).			
	8.	is attached hereto (pages specification, claims & abstract (claims), sheets drawings).	
	b.	has been communicate	ted by the International Bureau.		
	c.	is not required, as the	application was filed in the United States Rece	eiving Office (RO/US).	
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(3))			
	a. Cert	is attached hereto (pages specification, claims & abstract (claims), sheets drawings, page ificate of Translation).			
	b.	has been previously su	submitted under 35 U.S.C. 154(d)(4).		
7.		Amendments to the claims	of the International Application under PCT Arti	icle 19 (35 U.S.C. 371(c)(3)	
	a .	are attached hereto (required only if not communicated by the International Bureau).			
	b.	have been communicated by the International Bureau.			
	c.	have not been made; however, the time limit for making such amendments has MOT expired.			
	d.	have not been made a	have not been made and will not be made.		
8.		An English language transl:	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3).		
9.	a.	An oath or declaration	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4).		
	b. For	b. Declaration was submitted to the International Bureau during International Phase (see copies of Declaration (page Form PCT/RO/101 and Form PCT/IB/371 and first page of printed publication acknowledging receipt thereof attached).			
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5).					
	Ken		document(s) or information included:		
11.			Statement under 37 C.F.R. 1.97 and 1.98.		
12.		An assignment document for	An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.		
13.	a. b.	A FIRST preliminary at A SECOND or SUBSE	amendment. EQUENT preliminary amendment.		
14.		An Application Data Sheet	An Application Data Sheet under 37 C.F.R. § 1.76.		
15.		A substitute specification.	A substitute specification.		
16.		A change of power of attorney and/or address letter.			
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.			
18.		A second copy of the published international application under 35 U.S.C. 154(d)(4).			
19		A second conv of the English language translation of the international application under 35 U.S.C. 154(d)(4).			

20. Other items or information. Copy of Notification of Missing Requirements